BAI Announces 2020 Global Innovation Award Finalists
28.1.2021 16:30:00 EET | Business Wire | Press release
BAI announced the finalists for the 2020 BAI Global Innovation Awards, the industry’s prestigious awards program that celebrates new and innovative solutions in the financial services industry worldwide.
Now in its tenth year, the BAI Global Innovation Awards recognizes leading financial services organizations on a global scale. This year, the awards drew hundreds of nominations from industry leaders demonstrating how their organizations used innovation to tackle their challenges in creative, impactful ways. Each nomination is evaluated by the Innovation Circle, a panel of global financial services innovation leaders who weigh each submission on originality and impact on consumers, employees, communities and the industry to determine the top innovations of the year.
The 2020 BAI Global Innovation Awards finalists are:
Consumer Products of Services Innovation
- Bank Pekao S.A., Poland: PeoPay KIDS
- CaixaBank S.A., Spain: HolaBank – Onboarding + mortgageNow
- FNB Life, South Africa: Dynamic Life – Home
- Meridian Credit Union, Canada: Meridian’s Price Drop
- OneConnect Smart Technology Co., Ltd. (Shenzhen), China: Smart Fast Claim
Customer Experience Innovation
- Bank of Montreal, Canada: BMO AI Cashflow Prediction
- Commonwealth Bank of Australia: Bill Sense
- DBS Bank Ltd, Singapore: DBS Chatbot – Guided Conversation
- Finicity, United States: Empowering the Customer Through Open Banking & Credit Decisioning
- FNB Life, South Africa: We’ve Got You COVI(R)D
Human Capital Innovation
- Citizens Financial Group, United States: Jamie Virtual Career Assistant
- SberBank, Russia: Employee Digital Care Program
- Ziraat Bank, Turkey: Hidden Power of Communication
Internal Process Innovation
- CaixaBank S.A., Spain: The New Mobility Section at Now
- DenizBank, Turkey: Digital Scorecard
- ICICI Bank, India: OPTIMUS – Payment Invoicing and ID Card Issuance System
- OneConnect Smart Technology Co., Ltd. (ShenZhen), China: Smart Contract Cloud Platform
- SberBank, Russia: Contact Center Internal Improvement Process
Marketing Innovation
- Emirates NBD Bank, United Arab Emirates: Emirates NBD Anti-Phishing "It Wasn't Me" Campaign
- imaginTech S.A., Spain: New imagin, a New Way to Communicate
- Synchrony, United States: Millie: A Multi-Channel Personal Finance Platform for Women
RegTech Innovation
- Abu Dhabi Global Market Financial Center (ADGM), United Arab Emirates: ADGM and ClauseMatch collaborate to launch Regulation 2.0
- Fino Payments Bank, India: Enterprise Risk & Fraud Management solution
- KAL ATM Software, Germany: New approach to costly and disruptive ATM hardware upgrades
- Ping An Technology (Shenzhen) Co., Ltd., China: Pingan Beehive Federated Intelligence Platform
Small Business Products or Services Innovation
- Aliasware, Inc., United States: PayVus Small Business Credit Card
- Banco Bradesco, Brazil: Open Banking Initiative: Portal MEI, Solutions for the Individual Micro Entrepreneur
- İşbank, Turkey: TekCap
- RBC Ventures, Canada: Ownr
Societal and Community Impact Innovation
- Citi Ventures Studio, United States: City Builder
- Union Bank of the Philippines: UBX SeekCap
- Woodforest National Bank, United States: Woodforest CEI-Boulos Opportunity Fund
Congratulations to all the finalists of the 2020 BAI Global Innovation Awards. The winners will be announced in February. To learn more please visit BAI Global Innovation Awards.
About BAI
As a nonprofit, independent organization, BAI has delivered the financial services industry’s most actionable insights for more than 95 years, enabling leaders to make smart business decisions every day. We provide in-depth, proprietary research to more than 40 of the top US banks, support more than 2,100 financial services organizations with compliance and professional development training, provide trusted, relevant thought leadership through BAI Banking Strategies reports, podcasts and webinars, and offer specialized events and programs. For more information, visit www.bai.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210128005646/en/
Contact information
Holly Hughes
BAI, Chicago
hhughes@bai.org
+1 (312) 683-2305
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release
Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom